The European Commission has approved Sobi's Tryngolza (olezarsen) for treating adults with severe hypertriglyceridaemia (sHTG) with triglyceride levels ≥880 mg/dL. This label expansion targets approximately 700,000 patients in the EU5, following Phase 3 data showing a 73% reduction in triglycerides and an 83% decrease in acute pancreatitis events.
The European Commission approved Tryngolza (olezarsen) on Nov 17, 2026 for severe hypertriglyceridaemia, expanding the label from familial chylomicronemia syndrome to roughly 700,000 people with TG ≥880 mg/dL in the EU5. As holder of exclusive ex-US commercialisation rights (excluding Canada and China), Sobi gains a materially larger addressable market with Phase 3 data showing up to 73% triglyceride reduction and 83% fewer pancreatitis events.
- ▲ EC approval of Tryngolza for sHTG announced November 17, 2026
- ▲ Label expansion from FCS to ~700,000 EU5 patients with TG ≥880 mg/dL
- ▼ Commercial launch and reimbursement in EU member states still to be executed
- ▼ Competition from existing lipid-lowering therapies in sHTG